TNGX (Tango Therapeutics) Total Liabilities: $44.29 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNGX Tango Therapeutics Inc TNGX
54 GF Score
Price $27.67
GF Value $9.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Tango Therapeutics Total Liabilities?

Tango Therapeutics TNGX +2.22% 54 Total Liabilities is $44.29 Mil as of Mar. 2026. GuruFocus rates TNGX with a GF Score™ of 54/100 and a GF Value™ of $9.92 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Tango Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $44.29 Mil.

Tango Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($50.11 Mil) to Dec. 2025 ($52.51 Mil) but then declined from Dec. 2025 ($52.51 Mil) to Mar. 2026 ($44.29 Mil).

Tango Therapeutics's annual Total Liabilities declined from Dec. 2023 ($149.46 Mil) to Dec. 2024 ($116.98 Mil) and declined from Dec. 2024 ($116.98 Mil) to Dec. 2025 ($52.51 Mil).

Tango Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Tango Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tango Therapeutics Total Liabilities Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 155.41 186.99 149.46 116.98 52.51

Tango Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.55 102.94 50.11 52.51 44.29
TNGX
54GF Score
Tango Therapeutics Inc TNGX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tango Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tango Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.679+(30.832+3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=52.51

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=398.69-346.179
=52.51

Tango Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.33+(29.956+3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=44.29

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=435.792-391.506
=44.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $44.29 Mil mean?
Tango Therapeutics (TNGX) has a Total Liabilities of $44.29 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Tango Therapeutics and its competitors.
Is Tango Therapeutics' Total Liabilities too high?
Tango Therapeutics' current Total Liabilities is $44.29 Mil. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' Total Liabilities compare to LEGN and CAI?
Tango Therapeutics' Total Liabilities of $44.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Tango Therapeutics and its competitors. Tango Therapeutics's current Total Liabilities is $44.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.92, compared to a current price of $27.67 — trading 178.9% above its estimated fair value. The current Total Liabilities is $44.29 Mil. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current Total Liabilities is $44.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tango Therapeutics (TNGX) Overvalued in 2026?

Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued. The current stock price of $27.67 is trading 178.9% above its estimated GF Value™ of $9.92. GuruFocus considers Tango Therapeutics to be Significantly Overvalued.

Key valuation signals for TNGX:

  • Total Liabilities: $44.29 Mil
  • GF Value™: $9.92 vs. price of $27.67 (178.9% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tango Therapeutics Business Description

Address 201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score

Get the complete analysis for TNGX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.67
Price
$9.92
GF Value